In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin

Krysta Brown; Anthony A Donato

doi:10.7326/J22-0105

In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin

Ann Intern Med. 2023 Jan;176(1):JC9. doi: 10.7326/J22-0105. Epub 2023 Jan 3.

Authors

Krysta Brown¹, Anthony A Donato¹

Affiliation

¹ Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).

PMID: 36592466
DOI: 10.7326/J22-0105

Abstract

GRADE Study Research Group; Nathan DM, Lachin JM, Buse JB, et al. Glycemia reduction in type 2 diabetes-microvascular and cardiovascular outcomes. N Engl J Med. 2022;387:1075-88. 36129997.

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Drug Therapy, Combination
Humans
Hypoglycemic Agents / therapeutic use
Insulin Glargine / therapeutic use
Liraglutide / therapeutic use
Sitagliptin Phosphate / therapeutic use
Treatment Outcome

Substances

Insulin Glargine
Liraglutide
glimepiride
Sitagliptin Phosphate
Hypoglycemic Agents